PTGS2 and colorectal cancer: An abnormally higher expression of COX-2 in the colon has been associated with a worse prognosis in colorectal cancer patients [21], and this protein has been chosen as a pharmacological target to alleviate inflammation of post-inflammatory IBS [22].